Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB

The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of bortezomib alone has been reported. A terminal pro-apoptotic endoplasmic reticulum (ER) stress/unfolded protein response (UPR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Buontempo, Francesca, Orsini, Ester, Lonetti, Annalisa, Cappellini, Alessandra, Chiarini, Francesca, Evangelisti, Camilla, Evangelisti, Cecilia, Melchionda, Fraia, Pession, Andrea, Bertaina, Alice, Locatelli, Franco, Bertacchini, Jessika, Neri, Luca Maria, McCubrey, James A., Martelli, Alberto Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811463/
https://www.ncbi.nlm.nih.gov/pubmed/26593250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811463/
https://www.ncbi.nlm.nih.gov/pubmed/26593250

Ejemplares similares